Bifidobacterium and FMT in Chronic Hepatic Encephalopathy: Neuroinflammation Insights from [18F]PBR146 PET Imaging

Study Background and Research Question

Hepatic encephalopathy (HE) is a debilitating neuropsychiatric complication arising from chronic liver failure, marked by systemic inflammation, neuroinflammation, and cognitive disturbances. Increasing evidence implicates the gut–liver–brain axis in the pathogenesis and progression of HE, with the intestinal microbiota playing a pivotal role in modulating neuroinflammatory responses and metabolic homeostasis. However, the precise mechanisms linking gut dysbiosis, neuroinflammation, and HE remain poorly defined. Addressing this knowledge gap, the reference study by Kong et al. (European Journal of Neuroscience, 2025) investigates the comparative efficacy of two gut-targeted interventions—Bifidobacterium (BIF) and fecal microbiota transplantation (FMT)—in modulating neuroinflammation in a rat model of chronic HE, using advanced in vivo neuroimaging.

Key Innovation from the Reference Study

This study represents a significant methodological advance by employing [18F]PBR146 micro-PET/CT imaging to noninvasively monitor neuroinflammation in living rats. The tracer [18F]PBR146 targets the 18-kDa translocator protein (TSPO), a biomarker upregulated in activated microglia during neuroinflammatory states. While previous research indicated the potential of the gut microbiota to influence neuroinflammatory processes, Kong et al. uniquely combine region-specific PET neuroimaging with gut microbiome profiling to evaluate the direct effects of BIF and FMT interventions on both brain and gut in chronic HE. This approach allows for unprecedented spatial resolution in detecting subtle changes in neuroinflammation across distinct brain regions.

Methods and Experimental Design Insights

The study utilized a well-controlled experimental paradigm in which chronic HE was induced in rats via bile duct ligation (BDL), a validated model that recapitulates key features of human HE, including hyperammonemia, neuroinflammation, and behavioral deficits. Thirty rats were randomized into four groups:

• Sham-operated rats treated with normal saline (Sham + NS)
• BDL rats treated with normal saline (BDL + NS)
• BDL rats administered with Bifidobacterium (BDL + BIF)
• BDL rats administered with FMT (BDL + FMT)

After establishing chronic HE, animals underwent sequential behavioral assessments, fecal sampling for microbiota analysis, and in vivo PET/CT imaging using [18F]PBR146. Quantitative imaging analysis focused on %ID/g (percent injected dose per gram) values across the whole brain and specific regions of interest, complemented by biochemical (cytokine profiling) and pathological evaluations. Microbiome composition was characterized by 16S rRNA sequencing, with linear discriminant analysis (LDA) to pinpoint taxa enriched by each intervention.

Core Findings and Why They Matter

Key results from the reference paper include:

• Neuroinflammation Imaging: While global brain uptake of [18F]PBR146 did not significantly differ among groups (p = 0.053), regional analyses revealed that the BDL + BIF group exhibited significantly lower tracer uptake in specific regions (bilateral accumbens and retrosplenial cortex) compared to BDL + NS, indicating reduced neuroinflammation.
• Bifidobacterium vs. FMT: Bifidobacterium treatment effectively inhibited neuroinflammation in BDL rats, whereas FMT failed to reduce neuroinflammatory markers and, in some instances, may have exacerbated dysbiosis.
• Behavioral and Cytokine Outcomes: No significant differences were observed in behavioral test performance or cytokine (IL-1β, IL-6, IL-10, TNF-α) levels across groups, suggesting that regional neuroinflammatory changes precede or are more sensitive than these systemic measures.
• Microbiota Shifts: Microbiome profiling demonstrated distinct taxonomic shifts: Sham + NS rats were enriched with Parasutterella and Streptococcus, BDL + FMT with Enterococcus and Lactobacillus, and BDL + BIF with Enterorhabdus, indicating intervention-specific modulation of gut flora.

These findings have several meaningful implications. First, they suggest that not all gut-targeted therapies are equivalent in their capacity to reduce neuroinflammation in HE; Bifidobacterium appears superior to FMT in this setting, possibly owing to selective restoration of beneficial taxa. Second, [18F]PBR146 PET imaging enables the detection of subtle, region-specific neuroinflammatory changes that may not be captured by gross behavioral or systemic cytokine assessments—an important consideration for translational research and therapeutic evaluation.

Comparison with Existing Internal Articles

The present findings align with insights from the internal article “Bifidobacterium vs. FMT in Neuroinflammation: PET Imaging of HE Rats”, which also underscores the value of high-resolution neuroimaging in distinguishing the effects of gut-targeted interventions. Additionally, recent translational reviews such as “Sodium Picosulfate: Mechanistic Insights and Strategic Pathways” have highlighted the intersection of gastrointestinal motility agents and gut–brain axis research. Sodium Picosulfate, a well-characterized stimulant laxative for constipation treatment, is referenced as a model compound for investigating modifications in gut motility and their systemic effects, including on the gut–liver–brain axis. Although not a direct focus of the Kong et al. study, such mechanistic links support the broader relevance of validated agents like sodium picosulfate for experimental models probing neuroinflammatory and gastrointestinal interactions.

Limitations and Transferability

Several caveats warrant attention. The study’s findings are specific to the chronic HE rat model induced by BDL and may not generalize to all forms of liver disease or encephalopathy. The lack of significant differences in behavioral and systemic inflammatory markers highlights the complexity of linking neuroimaging findings to functional outcomes. Additionally, the efficacy of FMT in this model may have been confounded by the composition of donor microbiota or method of administration, underscoring the need for further optimization and standardization in preclinical FMT protocols.

Transferability to clinical settings depends on the availability of sensitive, noninvasive neuroimaging techniques and the ability to translate these preclinical interventions into safe, effective therapies in humans. As the field advances, integrating imaging biomarkers with functional and molecular readouts will be critical for comprehensive evaluation of gut–brain axis interventions.

Protocol Parameters

• HE induction: Bile duct ligation (BDL) surgery is performed to model chronic hepatic encephalopathy.
• Bifidobacterium treatment: Administered post-BDL; strain, dosage, and duration should align with referenced protocols for reproducibility.
• FMT intervention: Fecal slurry is typically prepared from healthy donors and administered post-BDL; donor selection and preparation protocols significantly impact outcomes.
• Imaging protocol: [18F]PBR146 PET/CT imaging is performed to assess neuroinflammation; regions of interest include accumbens and retrosplenial cortex.
• Microbiome analysis: Fecal samples are collected for 16S rRNA sequencing; LDA is used for identifying intervention-enriched taxa.
• Behavioral assessment: Standardized neurocognitive and locomotor tests are conducted to monitor HE progression.

Research Support Resources

For laboratory teams seeking to model gut–liver–brain axis interactions or evaluate the effects of gut-targeted interventions on neuroinflammation and gastrointestinal motility, validated research compounds are essential. Sodium Picosulfate (SKU B2027) from APExBIO is widely referenced as a high-purity, stable stimulant laxative. It functions by inhibiting the absorption of water and electrolytes in the intestines and promoting their secretion, facilitating bowel movements and enabling controlled studies of gut motility and its systemic consequences. Its chemical structure—disodium;[4-[pyridin-2-yl-(4-sulfonatooxyphenyl)methyl]phenyl] sulfate—and robust solubility profile make it suitable for preclinical workflows, including studies of neuroinflammation and chronic constipation management. For detailed protocols and validated use cases, researchers can refer to the internal review or consult the APExBIO product page for storage and handling recommendations.